TLR4/NF-κB-IN-1

TLR4/NF-κB-IN-1 (Compound 7x) is an orally available inhibitor that specifically targets the TLR4/NF-κB signaling pathway, offering anti-inflammatory effects and the ability to cross the blood-brain barrier. TLR4/NF-κB-IN-1 can reduce acute neuroinflammation in mice caused by LPS (HY-D1056) and downregulate the expression of TLR4, P-NF-κB and P-IκB-α proteins[1].

Product Specifications

CAS Number

[3050836-94-4]

UNSPSC

12352211

Target

IKK; NF-κB; Toll-like Receptor (TLR)

Type

Reference compound

Related Pathways

Immunology/Inflammation; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/tlr4-nf-κb-in-1.html

Purity

99.92

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

FC1=CC=C(CN2C=CC3=C(NC4=CC(NC(N5)=O)=C5C=C4)N=CN=C32)C=C1

Molecular Formula

C20H15FN6O

Molecular Weight

374.37

References & Citations

[1]Liang Xiong, et al. Design and synthesis of novel derivatives of bisepoxylignans as potent anti-inflammatory agents involves the modulation of the M1/M2 microglia phenotype via TLR4/NF-κB signaling pathway. Eur J Med Chem. 2025 Jan 15:282:117092.